A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base
Basal Cell Carcinomas (BCC) are the commonest form of skin cancer in the white population.
The face is where they most frequently occur and the nodular BCCs are the commonest type.
Curettage and cautery/electrodessication (C&C) has been an established way of management of
nodular BCCs for years, being a simple surgical procedure readily performed in outpatient
clinics with good aesthetic results and high cure rates. The purpose of this study is to
determine recurrence rates of nodular BCCs on the face removed with C&C followed by
application of Imiquimod cream to the base and further to achieve lower recurrence rates
than after treatment with C&C alone. Imiquimod is an immune response modifier with
anti-tumour effects already licensed for the treatment of superficial BCCs in the UK.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Basal Cell Carcinoma recurrence rates in 3 years
Lorna MacKintosh, Specialist Registrar
United Kingdom: Medicines and Healthcare Products Regulatory Agency